Vaxcyte (PCVX) Cash & Equivalents (2019 - 2026)

Vaxcyte (PCVX) has reported Cash & Equivalents for 8 consecutive years, with $260.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 24.8% year-over-year to $260.8 million; the TTM figure through Mar 2026 stood at $260.8 million (down 24.8% YoY), while the FY2025 annual figure was $174.0 million, down 55.15% from the prior year.
• Cash & Equivalents climbed to $260.8 million in Q1 2026 per PCVX's latest filing, from $174.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.1 billion in Q3 2024 and bottomed at $174.0 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $432.0 million across 5 years, with a median of $380.5 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 1109.91% — and 2025, when it sank 73.24%.
• Vaxcyte's Cash & Equivalents stood at $834.7 million in 2022, then plunged by 52.38% to $397.5 million in 2023, then dropped by 2.41% to $387.9 million in 2024, then slumped by 55.15% to $174.0 million in 2025, then jumped by 49.95% to $260.8 million in 2026.
• Business Quant data shows PCVX's Cash & Equivalents at $260.8 million in Q1 2026, $174.0 million in Q4 2025, and $281.1 million in Q3 2025.